RadNet, Inc. (RDNT)
RadNet, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $77.12, up 2.16% on the session, giving a market capitalisation of $6.06B. On trailing twelve-month figures it carries a trailing P/E of -289.38, a net margin of -0.9%. Its beta of 1.40 implies it has historically moved more than the broad market.
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
RadNet, Inc. is most often compared with the following Healthcare names: